These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35037561)

  • 1. Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Melén CM; Merrien M; Wasik AM; Panagiotidis G; Beck O; Sonnevi K; Junlén HR; Christensson B; Sander B; Wahlin BE
    Leuk Lymphoma; 2022 Jun; 63(6):1387-1397. PubMed ID: 35037561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
    Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83.
    Cerretani D; Collodel G; Brizzi A; Fiaschi AI; Menchiari A; Moretti E; Moltoni L; Micheli L
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32752303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
    Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
    PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoids in Oral Fluid: Limiting Potential Sources of Cannabidiol Conversion to Δ9- and Δ8-Tetrahydrocannabinol.
    Coulter C; Wagner JR
    J Anal Toxicol; 2021 Sep; 45(8):807-812. PubMed ID: 34137890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homegrown perceptions about the medical use and potential abuse of CBD and THC.
    McFadden BR; Malone T
    Addict Behav; 2021 Apr; 115():106799. PubMed ID: 33387977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
    Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
    Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.